人民财讯1月26日电，九安医疗（002432）1月26日发布2025年度业绩预告，预计2025年归母净利20.2亿 元—23.5亿元，同比增长21.05%—40.83%。报告期内，资管业务在大类资产配置方面表现良好。此外， 公司试剂盒类产品作为常规家用上呼吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳 定。 ...

Market Overview - The Shanghai Composite Index closed at 4132.61 points, down 0.09%, while the Shenzhen Component Index closed at 14316.64 points, down 0.85%. The ChiNext Index fell by 0.91%, and the STAR Market 50 Index decreased by 1.35% [1] Stock Performance - Among the tradable A-shares, 1604 stocks rose, accounting for 29.36%, while 3771 stocks fell. There were 77 stocks that hit the daily limit up, and 42 stocks that hit the daily limit down. Additionally, 53 stocks failed to hit the limit, resulting in an overall limit-up rate of 59.23% [1] - The sectors with the highest number of stocks hitting the limit up included non-ferrous metals, pharmaceuticals, and machinery, with 21, 11, and 9 stocks respectively [1] Specific Stock Highlights - Among the stocks that hit the limit up, 7 were ST stocks, including ST Jinglan and ST Jingji. Baiyin Nonferrous has recorded 5 consecutive limit-up days, the highest among all stocks [2] - In terms of limit-up order amounts, Hunan Gold, Mingyang Smart Energy, and Tianqi Co. had the largest amounts, with 4.443 billion, 871 million, and 732 million respectively. Hunan Gold resumed trading and achieved a limit-up on the news that spot gold prices surpassed $5000 for the first time, reaching a peak of $5111.17 per ounce, an increase of over 2% [2] Market Trends - According to Debon Securities, precious metals and non-ferrous metals are showing strong performance. Specifically, precious metals are leading in international commodities, with silver prices soaring and significant increases in tin, gold, and nickel prices. The domestic market reflects a similar trend with strong performances in precious metals, non-ferrous metals, and energy chemicals, with silver leading the gains [2] Order Strength Analysis - In terms of order strength (the proportion of limit orders to circulating A-shares), Zhongnong United, Hunan Gold, and Tianqi Co. showed significant strength, with ratios of 14.40%, 11.25%, and 7.92% respectively [3]

人民财讯1月26日电，1月26日，2026年"非遗贺新春.寻味中国年"主题推广暨非遗年货购物月在广东省 广州市启动。非遗年货购物月将持续至3月3日，各地将推出一批适宜春节期间购买消费的非遗好物、旅 游线路和体验服务，推动非遗成为创新消费场景、激发消费活力的新热点新动能。 ...

Group 1: Market Overview - On January 26, the main funds in the Shanghai and Shenzhen markets experienced a net outflow of 757.1 billion yuan, with the ChiNext index seeing a net outflow of 281.49 billion yuan and the CSI 300 index a net outflow of 95.23 billion yuan [1] - Among the 10 primary industry sectors, the non-ferrous metals sector had the highest increase at 4.57%, followed by the petroleum and petrochemical sector at 3.18% and the coal sector at 2.07% [1] - In contrast, the defense and military industry saw the largest decline at 4.47%, with the automotive, social services, electronics, real estate, and computer sectors also experiencing declines exceeding 2% [1] Group 2: Fund Inflows and Outflows by Industry - Six industries saw net inflows of main funds, with the pharmaceutical and biotechnology sector leading at 3.29 billion yuan, followed by the communication sector at 2.519 billion yuan, and both the non-bank financial and banking sectors exceeding 1.4 billion yuan [1] - Conversely, 25 industries experienced net outflows, with the electronics, power equipment, and defense industries each seeing outflows exceeding 11 billion yuan [1] Group 3: Individual Stock Performance - Two stocks, Wangsu Science & Technology and Tianfu Communication, had significant net inflows exceeding 1.1 billion yuan, with Wangsu Science & Technology seeing a net inflow of 1.719 billion yuan and a price increase of 20.03% [2][3] - A total of 120 stocks had net inflows exceeding 100 million yuan, with 23 stocks exceeding 300 million yuan [2] - On the other hand, over 270 stocks had net outflows exceeding 1 billion yuan, with the leading outflow from Xunwei Communication at 1.946 billion yuan, followed by Goldwind Technology at 1.864 billion yuan [4][5] Group 4: End-of-Day Fund Flows - At the end of the trading day, the main funds saw a net outflow of 15.61 billion yuan, with the ChiNext index experiencing a net outflow of 6.76 billion yuan [6] - Four stocks had net inflows exceeding 1 billion yuan at the end of the day, with Hikvision leading at 1.471 billion yuan and a price increase of 1.13% [6][7] - Conversely, 25 stocks had net outflows exceeding 700 million yuan, with CATL, Weichai Power, and Tongfu Microelectronics each seeing outflows exceeding 2 billion yuan [8][9]

人民财讯1月26日电，海科新源（301292）1月26日公告，公司与深圳市比亚迪（002594）锂电池有限公 司(简称"比亚迪锂电池")签署长期合作协议暨湖北项目管输合作协议，协议有效期三年，在协议有效期 内，海科新源以管输方式向比亚迪锂电池湖北项目供应协议所购产品每年至少10万吨。产品的实际采购 数量以双方签署的相关协议为准。 ...

截至今日（1月26日）收盘，上证指数报收4132.61点，下跌0.09%；深证成指收于14316.64点，下跌 0.85%。创业板指下跌0.91%；科创50指数下跌1.35%。 不含未开板新股，今日可交易A股中，上涨个股有1604只，占比29.36%，下跌个股有3771只。其中，收 盘封死涨停的有77只，跌停股有42只。另外，53股封板未遂，整体封板率为59.23%。 德邦证券指出，贵金属与有色金属表现强势。具体来看，国际商品中"贵金属领涨，银价飙升，锡、 金、镍价大涨"。国内市场同样呈现"贵金属、有色、能化强势，白银领涨"的格局。 从封单力度（封单量占流通A股比例）来看，中农联合、湖南黄金、天奇股份等力度较大，分别为 14.40%、11.25%、7.92%。 | | | | 1月26日涨停封单资金居前的个股 | | | --- | --- | --- | --- | --- | | 代码 | 简称 | 涨停封单额 (亿元) | 涨停板情况 | 涨停原因 | | 002155 | 湖南黄金 | 44.43 | 首板 | 重组复牌+黄金预增+湖南国资 | | 601615 | 明阳智能 | 8.71 | 3连板 ...

人民财讯1月26日电，1月26日，依米康（300249）发布业绩预告，2025年预计净利润2500万元至3700万 元，2024年同期则亏损8713.72万元。依米康表示，紧跟下游行业对精密散热产品需求不断扩张的市场 行情，确定了"锚定大客户"的经营策略，紧跟国内大厂建设需求，上市公司精密散热产品订单持续增 长。此外，依米康还持续加强海外订单的拓展，精密散热产品海外订单亦大幅增长。 ...

人民财讯1月26日电，现货白银日内涨超6%，报109.756美元/盎司，续创历史新高。 转自：证券时报 转自：证券时报 人民财讯1月26日电，现货白银日内涨超6%，报109.756美元/盎司，续创历史新高。 ...

转自：证券时报 人民财讯1月26日电，现货钯金站上2100美元/盎司，日内涨超4%。 转自：证券时报 人民财讯1月26日电，现货钯金站上2100美元/盎司，日内涨超4%。 ...

2024年，通化东宝的利润总额为-1.44亿元，归属于母公司所有者的净利润-4272.32万元，归属于母公司 所有者的扣除非经常性损益的净利润-919.54万元。 通化东宝（600867）1月26日晚发布2025年年度业绩预盈公告，经公司财务部门初步测算，预计2025年 实现归属于母公司所有者的净利润约为12.42亿元，与上年同期相比，将实现扭亏为盈。预计2025年实 现归属于母公司所有者的扣除非经常性损益的净利润约为4.02亿元。 通化东宝在2025年第三季度业绩说明会上介绍，2025年以来，公司国际化战略稳步推进，国际注册呈现 出扩面提速、多点开花的良好局面。 胰岛素方面，在新兴市场，公司胰岛素制剂产品已先后在乌兹别克斯坦、尼加拉瓜、缅甸、印尼、多米 尼加5个国家获批上市；在法规市场，公司门冬胰岛素美国BLA已获得美国食品药品监督管理局(FDA) 受理，后续将继续推进甘精胰岛素和赖脯胰岛素的BLA申报工作，并有序开展胰岛素类似物在欧洲 和"一带一路"共建国家的注册资料准备及申请工作。 GLP-1方面，公司与科兴制药合作开拓利拉鲁肽注射液海外市场，已通过埃及卫生部GMP现场审计并获 得哥伦比亚GMP证书，同 ...